CN1250277C - 一种具抗炎、镇痛、抑菌、利尿作用的药物 - Google Patents
一种具抗炎、镇痛、抑菌、利尿作用的药物 Download PDFInfo
- Publication number
- CN1250277C CN1250277C CN 200410022870 CN200410022870A CN1250277C CN 1250277 C CN1250277 C CN 1250277C CN 200410022870 CN200410022870 CN 200410022870 CN 200410022870 A CN200410022870 A CN 200410022870A CN 1250277 C CN1250277 C CN 1250277C
- Authority
- CN
- China
- Prior art keywords
- turmeric
- water
- ethanol
- volatile oil
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 80
- 229940079593 drug Drugs 0.000 title claims abstract description 71
- 230000001882 diuretic effect Effects 0.000 title claims abstract description 21
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 17
- 208000004880 Polyuria Diseases 0.000 title claims abstract description 16
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 3
- 230000001741 anti-phlogistic effect Effects 0.000 title abstract 3
- 230000003158 microbiostatic effect Effects 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 159
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 110
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 91
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 91
- 235000013976 turmeric Nutrition 0.000 claims abstract description 91
- 239000000341 volatile oil Substances 0.000 claims abstract description 87
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 75
- 239000000706 filtrate Substances 0.000 claims abstract description 65
- 239000000284 extract Substances 0.000 claims abstract description 60
- 239000007788 liquid Substances 0.000 claims abstract description 40
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 238000001914 filtration Methods 0.000 claims abstract description 16
- 238000001291 vacuum drying Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000012141 concentrate Substances 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 238000001256 steam distillation Methods 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims description 71
- 239000000843 powder Substances 0.000 claims description 64
- 235000012054 meals Nutrition 0.000 claims description 32
- 241000157835 Gardenia Species 0.000 claims description 24
- 238000009835 boiling Methods 0.000 claims description 22
- 230000000844 anti-bacterial effect Effects 0.000 claims description 17
- 239000007799 cork Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000011084 recovery Methods 0.000 claims description 14
- 241000132536 Cirsium Species 0.000 claims description 12
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 12
- 238000004821 distillation Methods 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 claims description 10
- 241000819233 Tribulus <sea snail> Species 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 229940047183 tribulus Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 229940126701 oral medication Drugs 0.000 claims description 9
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 244000008991 Curcuma longa Species 0.000 claims 16
- 229940052016 turmeric extract Drugs 0.000 abstract description 8
- 235000020240 turmeric extract Nutrition 0.000 abstract description 8
- 239000008513 turmeric extract Substances 0.000 abstract description 8
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract 4
- 241000972672 Phellodendron Species 0.000 abstract 3
- 244000111489 Gardenia augusta Species 0.000 abstract 2
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 2
- 241001533104 Tribulus terrestris Species 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 description 20
- 210000002700 urine Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 210000002683 foot Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 10
- 239000011591 potassium Substances 0.000 description 10
- 229910052700 potassium Inorganic materials 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 230000002485 urinary effect Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000029142 excretion Effects 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 7
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 7
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical group C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 235000014347 soups Nutrition 0.000 description 6
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 5
- 229940093265 berberine Drugs 0.000 description 5
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 210000004744 fore-foot Anatomy 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 229960002003 hydrochlorothiazide Drugs 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010061339 Perineal pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241001521901 Tribulus lanuginosus Species 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035911 sexual health Effects 0.000 description 1
- -1 sifted Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
项目 | 散剂 | 胶囊剂 |
制备工艺 | 按协日嘎四味汤散制备工艺称取药材、粉碎成中粉、过筛、混匀、即得。 | 姜黄600g粉碎成粗粉,加水14倍量水蒸汽蒸馏法提取挥发油8h,挥发油备用,余液过滤,滤液备用;黄柏360g加工成粗粉,7倍量70%乙醇回流提取三次,每次2h,合并滤液,回收乙醇,浓缩液备用;栀子480g、蒺藜600g二味粉碎成粗粉,加姜黄提取挥发油后的滤渣,加水9倍量,煎煮三次,每次2h,合并滤液,加入姜黄水提液,浓缩至 |
d=1.08,加乙醇使含醇量为60%,静置24h,过滤,滤液回收乙醇,加到黄柏浓缩液中浓缩,65℃真空干燥,得干浸膏。姜黄挥发油用35g CaHPO4吸附24h,备用。干浸膏粉碎粉碎成细粉,加微晶纤维素、乳糖,95%乙醇制粒,整粒,加吸附挥发油后的CaHPO4,再加入滑石粉、硬脂酸镁,混匀、装囊制备胶囊1000粒。 | |||
含量测定 | 小檗碱 | 每2g散剂含小檗碱2.4mg | 每粒胶囊含小檗碱为2.17mg(每粒胶囊含生药2g),小檗碱转移率为90.4% |
栀子苷 | 每2g散剂含栀子苷14.0mg | 每粒胶囊含栀子苷11mg(每粒胶囊含生药2g),栀子苷转移率为78.6% | |
挥发油 | 散剂服用方法为水煎煮后服用,姜黄挥发油损失量大 | 在提取工艺中对挥发油专门进行提取,挥发油无损失 |
组别 | 剂量(g/kg) | 肿胀度(mg) | 抑制率(%) |
对照组阿司匹林协日嘎散剂本发明胶囊本发明胶囊本发明胶囊 | -0.26.01.53.06.0 | 16.2±5.27.3±4.0***10.0±4.9**15.5±5.8*△10.9±4.5**△9.3±5.1**△ | 52.534.010.538.742.1 |
组别 | 剂量(g/kg) | 致炎前足跖体积(ml) | 致炎后不同时间足跖肿胀度(ml) | |||
1h | 2h | 4h | 6h | |||
对照组阿司匹林协日嘎散剂 | -0.12.8 | 1.03±0.071.00±0.121.04±0.08 | 0.64±0.140.39±0.10***0.50±0.10** | 0.57±0.150.38±0.11***0.45±0.07** | 0.48±0.110.30±0.11***0.35±0.13** | 0.34±0.080.21±0.09***0.28±0.09* |
本发明胶囊本发明胶囊本发明胶囊 | 0.71.42.8 | 1.10±0.070.98±0.101.13±0.09 | 0.55±0.08*△0.50±0.13**△0.39±0.10***△△ | 0.47±0.11*△0.38±0.10***△0.37±0.09***△△ | 0.39±0.13*△0.36±0.09**△0.30±0.07***△△ | 0.32±0.07*△0.28±0.06*△0.26±0.07**△△ |
组别 | 剂量(g/kg) | 扭体次数(次/15min) |
对照组阿司匹林协日嘎散剂本发明胶囊本发明胶囊本发明胶囊 | -0.26.01.53.06.0 | 26.9±9.98.8±8.9***20.5±12.7*22.0±8.2*△17.4±11.7*△15.8±10.9**△ |
菌种金黄色葡萄球菌甲型链球菌乙型链球菌大肠杆菌绿脓杆菌白色念珠菌 | MIC(mg/ml) | MBC(mg/ml) | ||
胶囊 | 散剂 | 胶囊 | 散剂 | |
50505050100100 | 505050100200200 | 100100100200-200 | 200200200200-200 |
组别 | 剂量(g/kg) | 动物数(只) | 死亡数(只) | 存活动物数(只) | 保护率(%) |
对照组氨苄青霉素协日嘎散剂本发明胶囊本发明胶囊本发明胶囊 | -0.16.01.53.06.0 | 101010101010 | 814654 | 29***6*4*△5*△6*△ | -9060405060 |
组别 | 剂量(g/kg) | 动物数(只) | 死亡数(只) | 存活动物数(只) | 保护率(%) |
对照组 | - | 10 | 9 | 1 | |
氨苄青霉素 | 0.1 | 10 | 2 | 8*** | 80 |
协日嘎散剂 | 6.0 | 10 | 4 | 6* | 60 |
本发明胶囊 | 1.5 | 10 | 7 | 3*△ | 30 |
本发明胶囊 | 3.0 | 10 | 5 | 5*△ | 50 |
本发明胶囊 | 6.0 | 10 | 3 | 7**△ | 70 |
组别 | 剂量(g/kg) | 尿排出量(ml/kg) | |
2h | 4h | ||
对照组氢氯噻嗪协日嘎散剂本发明胶囊本发明胶囊本发明胶囊 | -0.052.80.71.42.8 | 22.04±2.3226.60±2.53***23.06±3.22*24.40±3.56*△24.63±2.51**△24.94±2.77**△ | 25.96±3.2631.21±2.54***29.16±3.39**28.58±3.87*△29.35±2.82**△29.78±2.56***△ |
组别 | 剂量(g/kg) | 尿钾(mmol/kg) | 尿钠(mmol/kg) | 尿氯(mmol/kg) |
对照组氢氯噻嗪协日嘎散剂本发明胶囊本发明胶囊 | -0.052.80.71.4 | 0.464±0.2460.531±0.142*0.478±0.246*0.405±0.138*△0.495±0.129*△ | 0.564±0.1260.722±0.136**0.590±0.093*0.753±0.237**△0.691±0.152*△ | 0.546±0.2640.661±0.187*0.626±0.254*0.648±0.304*△0.583±0.207*△ |
本发明胶囊 | 2.8 | 0.533±0.181*△ | 0.655±0.097*△ | 0.547±0.116*△ |
组别 | 药物浓度(g生药/ml) | 给药途径 | 给药体积(ml/kg) | 剂量(g生药/kg) | 动物数(只) | 死亡动物数(只) | |
1天 | 2~7天 |
本发明散剂 | 1.81.8 | 灌胃灌胃 | 4040 | 7272 | 2020 | 00 | 00 |
组别 | 药物浓度(g生药/ml) | 给药体积(ml/kg) | 剂量(g生药/kg) | 动物数(只) | 体重变化(g) | |
实验前 | 第7天 | |||||
本发明散剂 | 1.81.8 | 4040 | 7272 | 2020 | 19.85±1.4619.40±0.99 | 22.85±1.2722.70±1.34 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410022870 CN1250277C (zh) | 2004-02-06 | 2004-02-06 | 一种具抗炎、镇痛、抑菌、利尿作用的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410022870 CN1250277C (zh) | 2004-02-06 | 2004-02-06 | 一种具抗炎、镇痛、抑菌、利尿作用的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1608662A CN1608662A (zh) | 2005-04-27 |
CN1250277C true CN1250277C (zh) | 2006-04-12 |
Family
ID=34763345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410022870 Expired - Lifetime CN1250277C (zh) | 2004-02-06 | 2004-02-06 | 一种具抗炎、镇痛、抑菌、利尿作用的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1250277C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169799A (zh) * | 2011-12-22 | 2013-06-26 | 湖南九典制药有限公司 | 一种治疗湿疹的中药组合物及其制备方法与应用 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732668B (zh) * | 2010-01-08 | 2012-05-23 | 朱志宏 | 一种治疗泌尿系统感染的中药组合物的制备方法 |
CN103169915A (zh) * | 2011-12-22 | 2013-06-26 | 湖南九典制药有限公司 | 一种制备治疗痤疮中药组合物的应用 |
CN102512629A (zh) * | 2011-12-22 | 2012-06-27 | 湖南九典制药有限公司 | 一种中药组合物用于制备治疗妇科炎症的应用 |
CN102488867A (zh) * | 2011-12-22 | 2012-06-13 | 湖南九典制药有限公司 | 一种中药组合物的新用途 |
CN103169916A (zh) * | 2011-12-26 | 2013-06-26 | 湖南九典制药有限公司 | 一种中药组合物用于制备治疗肾炎药物的应用 |
CN103110890B (zh) * | 2013-02-05 | 2015-03-18 | 董玉 | 协日嘎四味有效部位及其制备方法、质量检测方法和应用 |
CN106139002B (zh) * | 2016-07-20 | 2020-09-08 | 阿拉腾其木格 | 治疗小便闭止、尿频、尿急等的蒙药颗粒制剂及制备工艺 |
CN108205044A (zh) * | 2016-12-16 | 2018-06-26 | 内蒙古博奥现代蒙中药技术研究有限公司 | 一种蒙药复方协日嘎四味片的质量控制方法 |
CN106421674A (zh) * | 2016-12-27 | 2017-02-22 | 四川默森药业有限公司 | 一种治疗皮炎皮癣的药物组合物及其制备方法 |
CN114177264A (zh) * | 2021-12-23 | 2022-03-15 | 赤峰学院 | 用于治疗糖尿病及肾炎的中药组合物及其制备方法、应用 |
-
2004
- 2004-02-06 CN CN 200410022870 patent/CN1250277C/zh not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169799A (zh) * | 2011-12-22 | 2013-06-26 | 湖南九典制药有限公司 | 一种治疗湿疹的中药组合物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1608662A (zh) | 2005-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768308B (zh) | 一种用于治疗上呼吸道感染的药物组合物及其制备方法 | |
CN105078956A (zh) | 连翘苷元在制备预防或治疗肝损伤或肝衰竭药物中的应用 | |
CN1250277C (zh) | 一种具抗炎、镇痛、抑菌、利尿作用的药物 | |
CN101062289A (zh) | 治疗痛风的外用药物组合物 | |
US20170028007A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
CN101708241B (zh) | 一种祛湿止痒药物组合物 | |
CN101664446A (zh) | 热淋清浸膏及其制备方法和用途 | |
CN101732668B (zh) | 一种治疗泌尿系统感染的中药组合物的制备方法 | |
CN101032547A (zh) | 一种抗炎抗病毒的药物组合物 | |
CN101926791A (zh) | 一种水飞蓟宾二偏琥珀酸酯盐的磷脂复合物、其制备方法和用途 | |
CN102743663A (zh) | 一种治疗泌尿系感染的中药制剂及其制备方法 | |
CN1931302A (zh) | 一种治疗尿道结石、胆结石中药组合物及其制备方法 | |
CN1686423A (zh) | 一种含有黄芩苷和柴胡的药物组合物及其制备方法 | |
CN100509017C (zh) | 治疗胆道感染的药物及其制备方法 | |
CN1977900A (zh) | 一种用于银屑病等皮肤疾病的中药组合物 | |
CN1290528C (zh) | 一种治疗牙痛的药物 | |
CN100335083C (zh) | 治疗痔疮的中药制剂及其生产方法 | |
CN1853708B (zh) | 中药红豆蔻及其提取物的制药新用途 | |
CN1686424A (zh) | 一种含有黄芩和柴胡的药物组合物及其制备方法 | |
CN1278709C (zh) | 一种治疗感冒的药物及其制备方法 | |
CN101721437B (zh) | 用于治疗慢性咽炎的药物组合物的制备方法 | |
CN101966278B (zh) | 一种治疗泌尿道感染的中药及其制备方法 | |
CN1298351C (zh) | 一种治疗泌尿系感染的中药口服制剂及其制备方法 | |
CN100548308C (zh) | 用于自身免疫性疾病和器官移植排异的药物组合物 | |
CN100455309C (zh) | 一种治疗妇科炎症的复方中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 410005, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Patentee after: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. Address before: 410331 Liuyang Liuyang bio pharmaceutical Park Hunan Hunan nine Pharmaceutical Co., Ltd. Patentee before: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: 410205 8th floor, building A1, Lugu science and Technology Industrial Park, Wukuang, No.28, Ludian Road, Yuelu District, Changsha City, Hunan Province Patentee after: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. Address before: 410005, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Patentee before: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CX01 | Expiry of patent term |
Granted publication date: 20060412 |
|
CX01 | Expiry of patent term |